Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer

British Journal of Cancer

Volumn 99, Issue 10, 2008, Pages 1572-1578

  Sherrill, B ^a   Amonkar, M ^b   Wu, Y ^a   Hirst, C ^a   Stein, S ^b   Walker, M ^c   Cuzick, J ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Disease progression; Metastatic breast cancer; Survival

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BEVACIZUMAB; BIOLOGICAL FACTOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FADROZOLE; FLUOROURACIL; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINDESINE; VOROZOLE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; EFFECT SIZE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; SAMPLE SIZE; SENSITIVITY ANALYSIS; SURVIVAL TIME;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 55949094052     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604759     Document Type: Article

References (15)

1. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilas G, Paul J, Rosso R, Venturini M (2005) Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23: 5117-5125
2. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26: 1987-1992
3. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25: 5218-5224
4. Eiermann W (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(Suppl 1): S57-S62
5. Hackshaw A, Knight A, Barrett-Lee P, Leonard R (2005) Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 93: 1215-1221
6. Johnson K, Hill S, Stokes B, Berlin J, Freemantle N, Anthony D (2004) Developing Methodology for Validation and Comparison of Surrogate Markers in Randomized Clinical Trials (abstract). In 12th Cochrane Colloquium: Ottawa, Ontario, Canada
7. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL (2006) Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7: 741-746
8. Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hanel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U (2006) Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 24: 3919-3926
9. Lotz JP, Cure H, Janvier M, Asselain B, Morvan F, Legros M, Audhuy B, Biron P, Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S, Maraninchi D, Roche H, Gisselbrecht C (2005) High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41: 71-80
10. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M (2001) Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91: 2033-2038
11. Ng R, Pond GR, Tang PA, MacIntosh PW, Siu LL, Chen EX (2008) Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 19: 481-486
12. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A (2005) Disease-free survival vs overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials. J Clin Oncol 23: 8664-8670
13. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M, Possinger K (2005) Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23: 432-440
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
15. Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25: 4562-4568